Speaker: Prof. Mark E. Davis, California Institute of Technology, USA
Abstract: Nanoparticles are typically defined as colloidal particles with sizes in the range of 1 to 100 nm in diameter. Nanoparticles containing therapeutic entities are now called nanomedicines. My research group has been working on nanoparticle therapeutics since the mid-1990s, and we have invented nanomedicines that contain small molecules or nucleic acids that have been translated from the laboratory into experimental therapeutics for cancer clinical trials. This presentation begins with a brief summary of the properties of polymer-based nanoparticles can be tuned to perform the “right functions at the right place and at the right time” when administered systemically. A key advance in the field was the ability to build multifunctional nanoparticles where the functions work synergistically rather than annihilating each other. Examples demonstrating the behavior of polymer-based nanoparticles when carrying a variety of different payloads, e.g, small molecules, antibodies, nucleic acids will be provided. Comparisons to antibody drug conjugates (ADCs) will be highlighted. A summary of advantages and disadvantages of polymer-based nanoparticles will be provided with comparisons made to other types of delivery systems.
Time: Thursday, February 24, 2022
11 AM Eastern Time, 8 AM Pacific Time (USA)
4 PM (UK)
5 PM (Central European Time)
12 AM (China Standard Time)
3 AM (Australian Eastern Daylight Time)
Duration 1hr including Q&A
Register here
Biography: Mark E. Davis is the Warren and Katharine Schlinger Professor of Chemical Engineering at the California Institute of Technology, and is a member of the Comprehensive Cancer Center at the City of Hope and the Jonsson Comprehensive Cancer Center at UCLA. He has over 450 scientific publications, two textbooks and over 100 US patents. Professor Davis is a founding editor of CaTTech and has been an associate editor of Chemistry of Materials and the AIChE Journal. He is the recipient of numerous awards including the Colburn and Professional Progress Awards from the AIChE and the Somorjai, Ipatieff, Langmuir, Murphree and Gaden Prizes from the ACS. Professor Davis was the first engineer to win the NSF Alan T. Waterman Award. He was elected in the National Academy of Engineering in 1997, the National Academy of Sciences in 2006 and the National Academy of Medicine in 2011. In 2014, he received the Prince of Asturias Award for Technical and Scientific Research from the King of Spain. In 2015, he was elected into the National Academy of Inventors. Professor Davis’ research efforts involve materials synthesis in two general areas; namely, zeolites and other solids that can be used for molecular recognition and catalysis, and polymers for the delivery of a broad range of therapeutics. He is the founder of Insert Therapeutics Inc., Calando Pharmaceuticals, Inc. a company that created the first RNAi therapeutic to reach the clinic for treating cancer, Avidity Biosciences (RNA) and Dantari Pharmaceuticals. He is/has been a member of the scientific advisory boards of Symyx (Nasdaq: SMMX), Alnylam (Nasdaq: ALNY) and Intellia Therapeutics (Nasdaq: NTLA). Professor Davis has achieved All American Status for Masters Track and Field in the 400, 200 and 100 Meter Dashes. In 2011, he won the 400 Meter Dash for men of age 55 and older at the Masters World Championship.
Website: https://markdavisgroup.org
